Understanding the Burden of Illness Associated with Hypoparathyroidism Reported Among Patients in the PARADOX Study
Overview
Affiliations
Objective: Hypoparathyroidism is a rare disease caused by lack of parathyroid hormone (PTH) leading to hypocalcemia, hyperphosphatemia, and a variety of symptoms. This study aimed to quantify the clinical and social burden of illness from the perspective of affected patients.
Methods: A web-based instrument was developed with input from patients, clinical experts, and the Hypoparathyroidism Association. Qualifying participants were ≥18 years old, diagnosed with hypoparathyroidism for ≥6 months, and U.S. residents. Questions focused on demographics, diagnosis perceptions, current attitudes, medical management, current symptoms, acute episodes, comorbidities, personal life, and employment.
Results: A total of 374 adults (mean age, 49 ± 12 years; female, 85%) with hypoparathyroidism (mean duration, 13 ± 12 years; severe condition, 30.5%) completed the survey. Patients reported visiting a mean of 6 ± 8 physicians before and after their diagnosis. The majority strongly agreed with feeling unprepared to manage the condition at diagnosis (56%), that controlling their hypoparathyroidism is harder than expected (60%), and that they were concerned about long-term complications of their current medications (75%). More than 10 symptoms were experienced by 72% of patients in the preceding 12 months, despite current management regimens. Symptoms were experienced for a mean of 13 ± 9 hours/day. Hospital stays or emergency department visits were required by 79% of patients. 45% reported significant interference with their lives, 85% reported an inability to perform household activities, and 20% experienced a disease-associated change in employment status.
Conclusion: Patients with hypoparathyroidism have a high burden of illness and experience a broad spectrum of symptoms, with a multidimensional impact on their lives.
Bertocchio J, Soyer J, Grosset N, Bessonies D, Nidercorn C, Sido C JBMR Plus. 2025; 9(3):ziaf011.
PMID: 39990279 PMC: 11845852. DOI: 10.1093/jbmrpl/ziaf011.
Croft J, Ainsworth G, Corrigan N, Gordon K, Perry A, Twiddy M BMJ Open. 2025; 15(1):e092422.
PMID: 39890139 PMC: 11784174. DOI: 10.1136/bmjopen-2024-092422.
Hypoparathyroidism: Similarities and differences between Western and Eastern countries.
Yang Y, Deng Y, Sun L, Rejnmark L, Wang L, Pietschmann P Osteoporos Int. 2025; 36(3):391-402.
PMID: 39777494 DOI: 10.1007/s00198-024-07352-6.
Hypoparathyroidism after thyroidectomy: a matter of definition, experience and new adjuncts.
Kuczma P, Triponez F Gland Surg. 2024; 13(10):1873-1877.
PMID: 39544970 PMC: 11558303. DOI: 10.21037/gs-24-256.
McEntee P, Greevy J, Triponez F, Demarchi M, Cahill R BJS Open. 2024; 8(5).
PMID: 39468722 PMC: 11518927. DOI: 10.1093/bjsopen/zrae122.